For the most updated information about our hours of operation, services, procedures and Coronavirus, please visit our COVID-19 page.
BUFFALO, NY – Evergreen Health and the University at Buffalo Department of Medicine – HIV and Infectious Diseases are participating in a multicenter clinical trial investigating the safety and efficacy of a regimen to treat HIV that is administered in monthly injections. ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, is sponsoring the trial. The first investigational long-acting injections are scheduled during May. The injections will be administered at Evergreen Health.
“I am honored to have been selected to participate in this trial,” said Dr. Alyssa Shon, Principal Investigator of the Trial and Medical Director, Evergreen Health. Adherence is key to successful HIV therapy, and medication regimens that do not require daily dosing could transform how we treat HIV infection.”
The Antiretroviral Therapy as Long Acting Suppression (ATLAS) study is a global phase III study with a two-drug investigational regimen of long-acting, injectable cabotegravir (ViiV Healthcare) and long-acting injectable rilpivirine (Janssen Pharmaceuticals) in virally suppressed adults living with HIV. This injectable drug therapy, which is administered every four weeks, differs from most current antiretroviral drug therapy that is taken orally on a daily basis.
The University at Buffalo Department of Medicine – HIV and Infectious Diseases Division has been actively involved in HIV clinical trials for more than three decades. This clinical trial is another way that Evergreen and the University at Buffalo continue to collaborate to enhance HIV care in our region.
Evergreen Health fosters healthy communities by providing medical, supportive and behavioral services to individuals and families in Western New York – especially those who are living with chronic illness or who are underserved by the healthcare system.
University at Buffalo Department of Medicine
UBMD Internal Medicine has 144 respected Primary and Specialty Care doctors along with 170 staff members working in 16 hospital and outpatient clinic locations. Internal Medicine is the largest practice plan within UBMD Physicians’ Group.
UBMDIM physicians treat patients, conduct research and teach the next generation of doctors at UB’s Jacobs School of Medicine and Biomedical Sciences.